I “just want to encourage you with some substance,” Roberts added, “that we are in the process of the second American Revolution, which will remain bloodless if the left allows it to be.” ...

The average one-year price target for Revolution Medicines (NasdaqGS:RVMD) has been revised to 41.65 / share. This is an increase of 5.15% from the prior estimate of 39.61 dated March 28 ...

H.C. Wainwright raised the firm’s price target on Revolution Medicines (RVMD) to $64 from $62 and keeps a Buy rating on the shares following the Q3 report. The firm says several key clinical ...

Revolution Medicines (NASDAQ:RVMD – Free Report) had its target price increased by Needham & Company LLC from $61.00 to $68.00 in a report issued on Thursday morning,Benzinga reports.

Guggenheim analyst Michael Schmidt raised the firm’s price target on Revolution Medicines (RVMD) to $82 from $72 and keeps a Buy rating on the shares after the company presented initial Phase 1 ...

Piper Sandler analyst Joseph Catanzaro raised the firm’s price target on Revolution Medicines (RVMD) to $70 from $57 and keeps an Overweight rating on the shares after the company reported Q3 ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 16.66% ...

On Monday, Oppenheimer has increased the stock price target for Revolution (NASDAQ: RVMD) to $60 from the previous $55, while maintaining an Outperform rating on the stock. This adjustment comes ...

H.C. Wainwright raised the firm’s price target on Revolution Medicines (RVMD) to $62 from $56 and keeps a Buy rating on the shares. The firm says RMC-9805 delivered in KRASG12D+ pancreatic cancer.